Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
Malte W VetterleinStephanie A M WankowiczThomas SeisenRichard LanderBjörn LöppenbergFelix K-H ChunMani MenonMaxine SunJustine A BarlettaToni K ChoueiriJoaquim BellmuntQuoc-Dien TrinhMark A PrestonPublished in: Cancer (2017)
Patients with neuroendocrine tumors benefit from neoadjuvant chemotherapy, as evidenced by better overall survival and lower rates of non-organ-confined disease at the time of RC. For tumors with micropapillary differentiation, sarcomatoid differentiation, or adenocarcinoma, neoadjuvant chemotherapy decreased the frequency of non-organ-confined disease at the time of RC. However, this favorable effect did not translate into a statistically significant overall survival benefit for these patients, potentially due to the aggressive tumor biology. Cancer 2017;123:4346-55. © 2017 American Cancer Society.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- lymph node
- papillary thyroid
- sentinel lymph node
- neuroendocrine tumors
- end stage renal disease
- rectal cancer
- muscle invasive bladder cancer
- squamous cell
- squamous cell carcinoma
- newly diagnosed
- chronic kidney disease
- ejection fraction
- radiation therapy
- prognostic factors
- lymph node metastasis
- free survival
- patient reported outcomes
- early stage